Advertisement
U.S. markets open in 1 hour 6 minutes

Lipigon Pharmaceuticals AB (publ) (9RP.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.00010.0000 (0.00%)
As of 08:14AM CET. Market open.
Advertisement
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

Currency in SEK. All numbers in thousands
Breakdown
ttm
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
9,327
16,407
0
3,180
4,278
Operating Expense
29,759
28,779
37,742
44,371
12,102
Operating Income
-20,432
-12,372
-37,742
-41,191
-7,824
Net Non Operating Interest Income Expense
177
243
37
78
7
Pretax Income
-20,255
-12,128
-37,705
-41,113
-8,068
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-20,255
-12,128
-37,705
-41,113
-8,068
Diluted NI Available to Com Stockholders
-20,255
-12,128
-37,705
-41,113
-8,068
Basic EPS
0.04
-0.19
-2.12
-3.35
-0.64
Diluted EPS
0.04
-0.19
-2.12
-3.35
-0.64
Basic Average Shares
64,114
64,121
17,791
12,271
12,526
Diluted Average Shares
125,791
64,121
17,791
12,271
12,526
Total Operating Income as Reported
-20,432
-12,371
-37,742
-41,191
-7,824
Total Expenses
29,759
28,779
37,742
44,371
12,102
Net Income from Continuing & Discontinued Operation
-20,255
-12,128
-37,705
-41,113
-8,068
Normalized Income
-20,255
-12,128
-37,705
-41,113
-7,817
Interest Income
238
246
37
83
10
Interest Expense
61
3
0
5
3
Net Interest Income
177
243
37
78
7
EBIT
-20,194
-12,125
-37,705
-41,108
-8,065
EBITDA
-20,170
-12,101
-37,681
-41,085
-8,065
Reconciled Depreciation
24.2
24
24
23
0
Net Income from Continuing Operation Net Minority Interest
-20,255
-12,128
-37,705
-41,113
-8,068
Total Unusual Items Excluding Goodwill
-
-
-
0
-251
Total Unusual Items
-
-
-
0
-251
Normalized EBITDA
-20,170
-12,101
-37,681
-41,085
-7,814
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0